SCHEMBL6478495

SCHEMBL6478495

CCCCCCCCCCCCCCCCOCCOCCOCCON1C(=O)CCC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 1/20 0.45
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
THRB P10828 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
CES2 O00748 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16328702 0.89 ALOX12 (0.54) ALOX12MAPTKMT2AKDM4EPOLB
SCHEMBL31115536 0.89 ALOX12 (0.54) ALOX12MAPTKMT2AKDM4EPOLB
SCHEMBL6860661 0.89 ALOX12 (0.54) ALOX12MAPTKMT2AKDM4EPOLB
SCHEMBL19646456 0.89 ALOX12 (0.54) ALOX12MAPTKMT2AKDM4EPOLB
Triethylene Glycol SCHEMBL6478490 0.87 KMT2A (0.56) ALOX12MAPTKMT2AMEN1THRB
SCHEMBL9506369 0.87 ALOX12 (0.56) ALOX12MAPTKMT2ATHRBKDM4E
SCHEMBL12501215 0.81 ALOX12 (0.53) ALOX12MAPTKMT2AKDM4EPOLB
SCHEMBL22891256 0.80 FAAH (0.53) ALOX12FAAHMGLL
SCHEMBL863059 0.79 KMT2A (0.41) MAPTKMT2AMEN1THRBHTT
SCHEMBL5821258 0.79 KMT2A (0.41) MAPTKMT2AMEN1THRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956051-B1 Enkephalin conjugates NOBEX CORPORATION (US) 2005-10-18 US disclosed
US-6943148-B1 Methods for delivering therapeutics across blood-barrier and for altering receptor binding affinity NOBEX CORPORATION (US) 2005-09-13 US disclosed
US-6930090-B2 Methods of activating a receptor using amphiphilic drug-oligomer conjugates NOBEX CORPORATION (US) 2005-08-16 US disclosed
US-20040110735-A1 Methods of activating receptor using amphiphilic drug-oligomer conjugates BIOCON LIMITED (IN) 2004-06-10 US disclosed
US-6703381-B1 ADMINISTERING AMPHIPHILIC ENKEPHALIN-OLIGOMER CONJUGATE NOBEX CORPORATION 2004-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110735-A1 Methods of activating receptor using amphiphilic drug-oligomer conjugates OGFR, NGFR, LDLR ALOX12 1520/4885MAPT 1794/4885KMT2A 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.